Clinical Trials Logo

Filter by:
NCT ID: NCT03449485 Recruiting - Obesity, Morbid Clinical Trials

Bariatric Surgery and Pharmacokinetics of Chlorprothixene

Start date: January 2, 2018
Phase:
Study type: Observational

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on chlorprothixene.

NCT ID: NCT03449472 Recruiting - Obesity, Morbid Clinical Trials

Bariatric Surgery and Pharmacokinetics of Quetiapine

Start date: January 2, 2018
Phase:
Study type: Observational

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on quetiapine are investigated.

NCT ID: NCT03448783 Recruiting - Obesity, Morbid Clinical Trials

Bariatric Surgery and Pharmacokinetics of Apixaban

Start date: January 2, 2018
Phase:
Study type: Observational

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on apixaban.

NCT ID: NCT03448419 Completed - Heart Failure Clinical Trials

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Start date: March 20, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary objectives are to assess Patient-Reported Outcome (PRO)

NCT ID: NCT03448406 Completed - Heart Failure Clinical Trials

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Start date: March 20, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection fraction (LVEF > 40%). Secondary objectives are to assess Patient-Reported Outcome (PRO)

NCT ID: NCT03447769 Terminated - Clinical trials for Non-Small Cell Lung Cancer

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Canopy-A
Start date: March 16, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

NCT ID: NCT03447444 Completed - Dementia Frontal Clinical Trials

Music and Physical Activity in Persons With Dementia

Start date: November 11, 2014
Phase: N/A
Study type: Interventional

Fronto lobe dementia constitutes 10-20 % of dementia conditions within younger persons (>65). People with neuronal degeneration in frontal and temporal lobes demonstrate a decline in social conduct, apathy, loss of insight that is gradual and progressive. Family members often experience guilt and shame because of the patients' behavior before institutionalization, and different behavioral disorders will cause great challenges to family caregivers and to staff after institutionalization. Preservation of dignity, both in regards to the person being affected, and their relatives, therefore seem highly relevant both before and after institutionalization.

NCT ID: NCT03446547 Recruiting - NSCLC, Stage I Clinical Trials

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

ASTEROID
Start date: December 4, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months

NCT ID: NCT03446534 Recruiting - Clinical trials for Lower Respiratory Tract Infection

The Norwegian Antibiotics for Pneumonia in Children Study

NAPiC
Start date: March 7, 2018
Phase: Phase 4
Study type: Interventional

This study evaluates the effect of amoxicillin in the treatment of lower airway infections in preschool children. Half of the patients will receive amoxicillin, while the other half will receive placebo.

NCT ID: NCT03445923 Terminated - Infertility Clinical Trials

Can Time-lapse Parameters be Used to Predict Pregnancy of Human Embryos?

Start date: May 29, 2018
Phase: N/A
Study type: Interventional

All patients starting an IVF-treatment at the clinics, and meeting the inclusion criteria, will be offered to participate in the study. Randomization will be performed on day 5 and the patients will be allocated into either morphology only group or time-lapse group. Embryos will be cultured to day five according to the clinics own routines. All embryos in both groups will be cultured using time-lapse incubation. In the control group the embryo selection will be based only on traditional morphological evaluation and in the treatment group a time-lapse selection model (KID Score day 5) will be used to select the embryo.